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Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic
transmission: implications for long-term drug efficacy and low extrapyramidal
side-effects
Abstract
Aripiprazole has been used effectively to treat schizophrenia in the clinic ; however, its mechanisms
ofaction are not clear. This study examined how short- and long-term aripiprazole treatment affects
dopaminergic transmission in mesolimbic and nigrostriatal pathways. For comparison, the effects of
haloperidol and olanzapine treatment were also examined. Aripiprazole significantly increased D2
receptor mRNA expression and decreased tyrosine hydroxylase (TH) mRNA expression in the ventral
tegmental area (VTA) after 1- and 12-wk treatment, but had no effect in substantia nigra (SN) and nucleus
accumbens (NAc). Aripiprazole also decreased dopamine transporter (DAT) binding density in NAc (for 1and 12- wk treatment) and VTA (1-wk treatment). In contrast, haloperidol significantly increased D2
receptor binding density and decreased DAT binding density in NAc and caudate putamen (CPu) after 1and 12- wk treatment, and it also decreases DAT binding in VTA after 12-wk treatment. Olanzapine had
less widespread effects, namely an increase in D2 receptor mRNA in VTA after 12-wk treatment and
decreased DAT binding in NAc after 1-wk treatment. These results suggest that aripiprazole has selective
effects on the mesolimbic dopaminergic pathway. Selectively reducing dopamine synthesis in VTA is a
possible therapeutic mechanism for the long-term efficacy of aripiprazole in controlling schizophrenia
symptoms with reduced extrapyramidal side-effects.
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Aripiprazole diﬀerentially aﬀects mesolimbic
and nigrostriatal dopaminergic transmission:
implications for long-term drug eﬃcacy and
low extrapyramidal side-eﬀects
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Abstract
Aripiprazole has been used eﬀectively to treat schizophrenia in the clinic ; however, its mechanisms of
action are not clear. This study examined how short- and long-term aripiprazole treatment aﬀects dopaminergic transmission in mesolimbic and nigrostriatal pathways. For comparison, the eﬀects of haloperidol and olanzapine treatment were also examined. Aripiprazole signiﬁcantly increased D2 receptor
mRNA expression and decreased tyrosine hydroxylase (TH) mRNA expression in the ventral tegmental
area (VTA) after 1- and 12-wk treatment, but had no eﬀect in substantia nigra (SN) and nucleus accumbens
(NAc). Aripiprazole also decreased dopamine transporter (DAT) binding density in NAc (for 1- and 12wk treatment) and VTA (1-wk treatment). In contrast, haloperidol signiﬁcantly increased D2 receptor
binding density and decreased DAT binding density in NAc and caudate putamen (CPu) after 1- and 12wk treatment, and it also decreases DAT binding in VTA after 12-wk treatment. Olanzapine had less
widespread eﬀects, namely an increase in D2 receptor mRNA in VTA after 12-wk treatment and decreased
DAT binding in NAc after 1-wk treatment. These results suggest that aripiprazole has selective eﬀects on
the mesolimbic dopaminergic pathway. Selectively reducing dopamine synthesis in VTA is a possible
therapeutic mechanism for the long-term eﬃcacy of aripiprazole in controlling schizophrenia symptoms
with reduced extrapyramidal side-eﬀects.
Received 2 October 2008 ; Reviewed 4 November 2008 ; Revised 16 December 2008 ; Accepted 30 December 2008 ;
First published online 10 February 2009
Key words : Antipsychotics, dopamine D2 receptor, dopamine transporter, tyrosine hydroxylase, ventral
tegmental area.

Introduction
Aripiprazole is a newly introduced antipsychotic
drug, with clinical eﬃcacy to control both positive and
negative symptoms, which has been recommended as
a ﬁrst-line therapy for the treatment of schizophrenia
(Cassano et al. 2007 ; DeLeon et al. 2004). An advantage
of aripiprazole over existing antipsychotics is a
favourable safety and tolerability proﬁle, including a
low incidence of extrapyramidal symptoms (EPS)
compared with typical antipsychotics (such as haloperidol), and a low incidence of weight gain and other
Address for correspondence : Dr C. Deng, School of Health Sciences,
University of Wollongong, Wollongong, NSW 2522, Australia.
Tel. : +61 2 4221 4934 Fax : +61 2 4221 5945
Email : chao@uow.edu.au

metabolic syndromes compared with other atypical
antipsychotics (such as olanzapine) (DeLeon et al.
2004). However, the mechanisms underlying its clinical eﬃcacy and improved safety and tolerability are
not well understood. A unique pharmacology of aripiprazole has been proposed to explain its favourable
clinical proﬁle : unlike other antipsychotics, aripiprazole has both partial agonist and antagonist activity at the dopamine D2 receptor (Hirose et al. 2004 ;
Shapiro et al. 2003). It is also a partial agonist to 5-HT1A
receptors and a partial antagonist to 5-HT2A receptors,
a so-called dopamine and 5-HT stabilizer. However,
there is evidence that at therapeutic doses, aripiprazole exhibits low levels of 5-HT1A and 5-HT2A receptor occupancy and activity (Wolﬀ et al. 2003 ;
Wood & Reavill, 2007), and acts predominantly on
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dopamine D2 receptors (Urban et al. 2007 ; Wood &
Reavill, 2007).
Dopaminergic neurons have two major projections
which are derived from the mesencephalon : the mesolimbic pathway, in which the ventral tegmental area
(VTA) projects to nucleus accumbens (NAc), and the
nigrostriatal pathway, in which the substantia nigra
(SN) projects to caudate putamen (CPu). Blockade of
dopamine D2 receptor activity in the mesolimbic
pathway is the main mechanism of antipsychotic drug
action (Kapur & Mamo, 2003). On the other hand,
the EPS side-eﬀects of typical antipsychotics (such as
haloperidol) relates to blockade of D2 receptors in the
SN–striatal pathway (Stephen & Stahl, 2003). Whether
aripiprazole exerts its eﬀects solely through partial
agonism on D2 receptors (Burris et al. 2002 ; Wood &
Reavill, 2007) or due to functionally selective activity
at D2 receptors (Lawler et al. 1999 ; Mailman, 2007 ;
Shapiro et al. 2003 ; Urban et al. 2007) is controversial.
Aripiprazole is a partial agonist at human D2L
receptors coupled to the inhibition of forskolinstimulated cAMP accumulation (Burris et al. 2002). It
has been suggested that aripiprazole is not simply a
partial agonist, but a drug with functional selectivity,
exerting eﬀects diﬀerentially depending on the cellular
location of the targeted receptor (Shapiro et al. 2003).
For example, it acts as an agonist on pre-synaptic D2
autoreceptors, whereas it also acts as an antagonist at
post-synaptic D2 receptors (Kikuchi, 1995 ; Shapiro et al.
2003). Recently aripiprazole has been found to act as a
potent partial agonist at D2 receptor-mediated signalling responses, such as the potentiation of arachidonic
acid release, and as a weak partial agonist using
MAPK (mitogen-activated protein kinase) phosphorylation, but lacked agonist activity on receptor internalization (Urban et al. 2007). These results support
aripiprazole as being a functionally selective D2 receptor ligand rather than a simple partial agonist
(Mailman, 2007).
As mentioned above, aripiprazole has less EPS sideeﬀects, which could be attributed to its partial agonism
at D2 receptors, in which some signals to postsynapses can be persistently generated although the
post-synaptic D2 receptors are fully occupied (Hirose
et al. 2004). However, it is possible that aripiprazole
is not only limited to straightforward receptor–drug
interaction but, may also have diﬀerential eﬀects on
the mesolimbic and nigrostriatal dopaminergic pathways.
In-vivo microdialysis studies have found that acute
aripiprazole treatment increases dopamine release
in the medial prefrontal cortex and hippocampus
(Bortolozzi et al. 2003 ; Zocchi et al. 2005) and elevates

3,4-dihydroxyphenylacetic acid (the major metabolite
of dopamine) in the medial prefrontal cortex and
striatum (Jordan et al. 2004). The dopamine transporter
(DAT) regulates the re-uptake of free dopamine from
the intra-synaptic cleft. It is the primary mechanism
for inactivation of dopamine following its release into
the synapse (Iversen, 1971). DAT binding density may
therefore reﬂect levels of free dopamine in the intrasynaptic cleft. However, it is unclear whether aripiprazole, particularly chronic treatment, aﬀects DAT
binding density. Furthermore, although aripiprazole
has been reported to reduce dopamine synthesis and
tyrosine hydroxylase activity (TH ; a rate-limiting
enzyme for the synthesis of dopamine) in reserpinetreated rodents through action at pre-synaptic dopamine autoreceptors (Kikuchi, 1995), it is unclear
whether aripiprazole aﬀects TH mRNA expression.
Therefore, in the present study, we examined the
selective eﬀects of short-term (1-wk) and chronic
(12-wk) aripiprazole treatment on D2 receptor and TH
mRNA expression, and binding densities of D2 receptor and DAT in the mesolimbic and nigrostriatal dopaminergic pathways. For comparison, the eﬀects of
haloperidol and olanzapine treatment were also examined.

Methods
Animals and experimental procedures
Sprague–Dawley rats (220–250 g) were obtained from
the Animal Resource Center (Perth, Australia). Upon
arrival, rats were housed individually in environmentally controlled conditions (temperature 22 xC, 12h light/dark cycle, lights on 07:00 hours), and had
ad-libitum access to water and standard laboratory
chow diet. After 1 wk adaptation to the new environment, they were treated with aripiprazole (2.25 mg/
kg.d ; Otsuka, Japan), olanzapine (1.5 mg/kg.d ;
Eli Lilly, USA), haloperidol (0.3 mg/kg.d, Sigma,
Australia), or vehicle (control) (Han et al. 2008a). The
daily dosage was divided into three equal amounts
and all rats were treated three times a day (06:00, 14:00,
22:00 hours) orally by specially prepared drug pellets
as described previously (Han et al. 2008b ; Huang et al.
2006). Each drug group was randomly subdivided
into short-term (1-wk, n=5) and chronic (12-wk, n=5)
treatment groups. Rats were sacriﬁced 48 h after the
last drug treatment. All experimental procedures were
approved by the Animal Ethics Committee, University
of Wollongong, and complied with the Australian
Code of Practice for the Care and Use of Animal for
Scientiﬁc Purposes.

Aripiprazole aﬀects dopaminergic transmission
Histology
All rats were sacriﬁced by carbon dioxide asphyxiation between 07:00 and 09:00 hours, in order to
minimize the variation of circadian mRNA expression.
Brains were immediately removed and frozen in
liquid nitrogen. Coronal brain sections (14 mm) were
cut at x17 xC a cryostat and thaw-mounted onto
polysine-coated slides. For in-situ hybridization, sections were immediately ﬁxed in ice-cold phosphate
buﬀer containing 4 % paraformaldehyde. Acetylation
was carried out in 0.25 % acetic anhydride in 0.1 M
triethanolamine buﬀer (pH 8.0) for 10 min. Sections
were then dehydrated in ethanol and stored at x20 xC
until use. For autoradiography, the sections were
stored at x20 xC after cutting until use without ﬁxation. Identiﬁcation of neuroanatomical structures was
according to a standard rat brain atlas (Paxinos &
Watson, 1997).
In-situ hybridization
The protocol followed that previously described
(Huang et al. 2006). Brieﬂy, the speciﬁc antisense hybridization probes for the D2 receptor were :
5k-cat gat aac ggt gca gag ttt cat gtc ctc agg gtg ggt aca
gtt gcc-3k
(NM010077, encoding bases 853–900),
5k-gac cca ttg aag ggc cgg ctc cag ttc tgc ctc tcc aga tca
tca tc-3k
(NM010077, encoding bases 157–203),
and for TH :
5k-tgg gtc agg gtg tgc agc tca tcc tgg acc ccc tct aag gag
cg-3k
(NM009377, encoding bases 1437–1480).
No sequences bearing signiﬁcant homology to the designed probes were found in the Gene Bank (NCBA).
All oligonucleotide probes were terminally labelled
with 10-fold molar excess of [35S]dATP (speciﬁc activity 1000 Ci/mmol, Amersham, UK) and terminal
transferase (Promega, USA), and puriﬁed over a
MicroSpin G-50 column (Amersham). The probe concentration was 107 cpm of 35S-labelled probes in 750 ml
hybridization solution. Hybridization was performed
by incubating sections in hybridization buﬀer [50 %
deionized formamide, 4r SSC, 10 % dextran sulfate,
1r Denhardt’s solution, 0.2 % sheared salmon sperm
DNA, 0.1 % long-chain polyadenylic acid, 0.012 %
heparin, 20 mM sodium phosphate (pH 7.0), 106/75 ml
labelled probe and 5 % DTT] at 37 xC for 16 h. Nonspeciﬁc hybridization was determined by including
100-fold molar excess of non-labelled probes in the
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respective hybridization solution. After hybridization,
sections were washed in 1r SSC buﬀer at 55 xC for
3r20 min followed by 1 h incubation in 1r SSC buﬀer
at room temperature. Finally, sections were dipped
sequentially in Milli-Q water, 70 % ethanol and 95 %
ethanol before air-drying and exposure to Hyperb-max ﬁlm (Amersham). After exposure (4 wk for D2
receptor and 2 wk for TH) in-situ hybridization ﬁlms
were developed using standard procedures. The sections containing positive signals were dipped in the
emulsion solution (Amersham) and exposed (6 wk for
D2 receptor and 4 wk for TH). This allows further
examination of positive signals at cellular level and
conﬁrmation of the results from the ﬁlm. As in our
previous work (Huang et al. 2006), all ﬁlms were
analysed using a computer-assisted image analysis
system, Multi-Analyst, connected to a GS-690 Imaging Densitometer (Bio-Rad, USA). Quantiﬁcation of
mRNA expression levels in various brain regions were
performed by measuring the average density of each
region. Values were then compared against a 14Clabelled autoradiographic standard (Amersham).
D2 receptor binding
Sections were preincubated in 50 mM Tris–HCl,
120 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2,
0.1 % ascorbic acid buﬀer (pH 7.4) for 30 min at room
temperature to remove endogenous ligands. Sections
were then incubated at room temperature for 1 h in
the same buﬀer containing 5 nM [3H]raclopride (speciﬁc activity 60.1 Ci/mmol ; PerkinElmer, USA). Nonspeciﬁc binding was determined in the presence of
10 mM butaclamol. The sections were then washed
2r5 min in ice-cold buﬀer and rinsed brieﬂy in icecold distilled water. Sections were then dried under a
stream of cold air.
DAT binding
Sections were preincubated in 50 mM Tris–HCl containing 120 mM NaCl and 0.1 % BSA (pH 7.4) for
20 min at 4 xC and then incubated for 2 h in the same
buﬀer containing 15 nM [3H]WIN 35,428 (speciﬁc
activity 85.6Ci/mmol ; PerkinElmer). Non-speciﬁc
binding was determined in the presence of 50 mM
benztropine. The sections were washed 2r1 min in
ice-cold buﬀer. After a brief rinse in ice-cold distilled water, the slides were rapidly dried under a
stream of cold air.
Autoradiographic images were produced using a
Beta image camera (BioSpace, France) as previously
described (Deng & Huang, 2005). The exposure time
was 3.5 h at a high-resolution setting. A series of
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sections with a known amount of ligand was used as a
standard in all scans. Quantitative analysis of these
images was performed with b-Image Plus (version 4 ;
BioSpace). The density of the binding signal was ﬁrst
expressed in counts per minute per square millimetre
(cpm/mm2) of area selected and was then converted
into femtomoles of radioligand bound per milligram
tissue equivalent (fmol/mg TE) by comparing with
the standard.

(a)

Bregma –4.92 mm

VTA

*
(b)

(e)

Statistical analysis
The data was analysed statistically using SPSS version
15.0 software (SPSS Inc., USA). Data for each brain
area were analysed by two-way ANOVA (drug treatmentrtreatment duration), followed by Tukey–
Kramer–HSD post-hoc analyses. Pearson’s correlations
were used to assess the relationships between D2 receptor mRNA expression, TH mRNA expression, D2
receptor binding and DAT binding.

(c)

Control

(f )

Control

(d)

Aripiprazole

(g)

Aripiprazole

Results
D2 receptor mRNA expression
Diﬀerential expression of D2 receptor mRNA was observed in NAc core (NAcC), NAc shell (NAcS), CPu,
SN and VTA. Examples of D2 receptor mRNA expression are presented in Fig. 1.
CPu. There were signiﬁcant eﬀects of drug treatment
(F3,32=5.712, p=0.003) and treatment duration (F1,39=
7.066, p=0.012) on D2 mRNA expression in CPu, but
no signiﬁcant interaction between the two factors
(F3,32=0.697, p=0.561). After 1-wk treatment, only the
aripiprazole group (237.9¡2.5 nCi/g TE) had signiﬁcantly higher D2 receptor mRNA expression compared
to the control group (206.7¡10.7, p=0.031 ; Fig. 2 d).
However, after 12-wk treatment, no signiﬁcant diﬀerence in D2 receptor mRNA expression was observed
between the aripirazole and control groups (p=0.471 ;
Fig. 2 d). Olanzapine and haloperidol groups also did
not signiﬁcantly diﬀer from controls in D2 receptor
mRNA expression (all p>0.300 ; Fig. 2 d).
VTA. There were signiﬁcant eﬀects of drug treatment
(F3,32=11.243, p=0.000) and treatment duration
(F1,39=4.770, p=0.036) on D2 mRNA expression in
VTA. However, there was no signiﬁcant interaction
between the two factors (F3,32=2.350, p=0.091). Compared to the control group, aripiprazole treatment signiﬁcantly increased the level of D2 receptor mRNA
expression in the 1-wk (aripiprazole 256.8¡6.3 vs.
control 203.1¡10.6, p=0.008 ; Fig. 1 b–d and Fig. 2 b)

Fig. 1. (b–d ) D2 receptor mRNA expression and (e–g) tyrosine
hydroxylase (TH) mRNA expression in the ventral tegmental
area (VTA) after 1-wk aripiprazole treatment. (a) The
schematic diagram is adapted from a rat brain atlas (Paxinos
& Watson, 1997). (b) Low magniﬁcation ﬁlms of D2 receptor
mRNA expression. (c, d ) High magniﬁcation emulsion
autoradiographs of D2 receptor mRNA expression in VTA.
(e) Low magniﬁcation ﬁlms of TH expression. ( f, g) High
magniﬁcation emulsion autoradiographs of TH mRNA
expression in VTA. * Indicates where high magniﬁcation
autoradiographs were taken. Scale bars : (b, e), 2 mm ; (c, d,
f, g), 50 mm.

and 12-wk (aripiprazole 254.2¡10.2 vs. control 205.1¡
5.1, p=0.002 ; Fig. 2 b) treatment groups. However,
compared to controls, olanzapine and haloperidol had
signiﬁcantly increased D2 receptor mRNA expression
only in the 12-wk treatment groups (olanzapine
246.7¡5.7 vs. control 205.1¡5.1, p=0.008 ; haloperidol
244.4¡9.1 vs. control, p=0.013 ; Fig. 2 b) but not in the
1-wk treatment groups (all p>0.299 ; Fig. 2 b). There
were no signiﬁcant eﬀects of drug treatment on D2 receptor mRNA expression in NAcC (Fig. 2a), NAcS,
and SN (Fig. 2 e).
TH mRNA expression in VTA and SN
There was a signiﬁcant eﬀect of drug treatment on the
level of TH mRNA expression in VTA (F3,32=14.5,

Aripiprazole aﬀects dopaminergic transmission
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Fig. 2. Expression of (a, b, d, e) D2 receptor mRNA and (c, f ) tyrosine hydroxylase (TH) mRNA in rats treated with either
aripiprazole (Ari), olanzapine (Olz), haloperidol (Hal), or vehicle (Con). NAcC, Nucleus accumbens core ; CPu, caudate
putamen ; SN, substantia nigra ; VTA, ventral tegmental area. Compared to control : * p<0.05, ** p<0.01, *** p<0.001. %, 1-wk
treatment ; &, 12-wk treatment.

p=0.000), but no signiﬁcant eﬀect of treatment period
(F1,39=1.2, p=0.287). There was also no interaction
between the two factors (F3,32=0.7, p=0.554). Compared to the control group, TH mRNA expression
levels were signiﬁcantly decreased in the aripiprazole
group after 1-wk (aripiprazole 319.6¡8.4 vs. control
460.3¡22.0, p=0.001 ; Figs 1 e–g, 2 c) and 12-wk (aripiprazole 312.1¡8.4 vs. control 422.2¡19.9, p=0.024 ;
Fig. 2 c) treatment. However, olanzapine and haloperidol treatment did not diﬀer from controls in TH
mRNA expression levels in VTA (Fig. 2 c). There was
no signiﬁcant eﬀect of drug treatment on TH mRNA
expression in SN (F3,32=2.3, p=0.092 ; Fig. 2 f ). It is
interesting that in the VTA, D2 receptor mRNA expression was negatively correlated with TH mRNA
expression (r=x0.449, p=0.004 ; Fig. 3 a).
D2 receptor binding
Examples of D2 receptor binding are presented in
Fig. 4c.
NAcC and NAcS. There were signiﬁcant eﬀects of drug
treatment on D2 receptor binding densities in NAcC
(F3,32=16.827, p=0.000) and NAcS (F3,32=12.572,
p=0.000) ; however, there were no eﬀects of treatment
duration in NAcC (F1,39=0.054, p=0.817) and NAcS
(F1,39=0.062, p=0.805). There was also no signiﬁcant

interaction between the two factors in the NAcC
(F3,32=1.199, p=0.326) and NAcS (F3,32=2.226, p=
0.104). Compared to the control group, only haloperidol treatment signiﬁcantly increased binding densities in these brain areas after 1- and 12-wk treatment
in these brain regions (NAcC, 1 wk : haloperidol 89.4¡
4.1 fmol/mg TE vs. control 69.4¡2.1, p=0.003 ; 12 wk :
haloperidol 85.5¡4.7 vs. control 68.2¡1.9, p=0.005 ;
Fig. 5 a. NAcS, 1 wk : haloperidol 79.9¡2.5 vs. control
65.2¡3.7, p=0.030 ; 12 wk : haloperidol 79.1¡1.8 vs.
control 58.9¡2.1, p=0.002).
CPu. There was a signiﬁcant eﬀect of drug treatment
on D2 receptor binding density in CPu (F3,32=8.318,
p=0.000), but no eﬀect on treatment duration (F1,39=
1.622, p=0.212). There was also no signiﬁcant interaction between the two factors in CPu (F3,32=0.195,
p=0.899). Compared to the control group, only haloperidol treatment signiﬁcantly increased binding
densities after 1- and 12-wk treatment (1 wk : haloperidol 146.9¡5.0 vs. control 120.4¡4.6, p=0.008 ;
12 wk : haloperidol 143.9¡8.1 vs. control 109.2¡4.6,
p=0.020 ; Fig. 5 b).
However, haloperidol treatment had no eﬀect on D2
receptor binding density in SN or VTA (Fig. 5 c).
Furthermore, aripiprazole and olanzapine treatments
did not aﬀect D2 receptor binding in any of these brain
regions examined (Fig. 5a–c).
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there was a tendency for binding to be decreased after
12-wk olanzapine treatment (olanzapine 30.3¡2.7 vs.
control 36.0¡3.8, p=0.109 ; Fig. 5 d).

(a)
TH mRNA expression (nCi/g TE)

600
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300
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160

180
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240

260

280

CPu. There was a signiﬁcant eﬀect of drug treatment
(F3,32=5.338, p=0.004), but no eﬀect of treatment duration (F1,39=0.258, p=0.615) on DAT binding in CPu.
There was also no signiﬁcant interaction between the
two factors (F3,32=1.335, p=0.280). As shown in Fig.
5 e, compared to the controls, haloperidol signiﬁcantly
decreased DAT binding density after 1- and 12-wk
treatment (Fig. 5 e). However, aripiprazole and olanzapine treatments did not aﬀect DAT binding in CPu
(Fig. 5 e).

D2 receptor mRNA expression (nCi/g tissue TE)

Binding density of DAT (fmol/mg TE)

(b)
4.5
4.0
3.5
3.0
2.5
2.0
1.5
3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

Binding density of D2 receptor (fmol/mg TE)
Fig. 3. (a) A signiﬁcant negative correlation was found
between D2 receptor and tyrosine hydroxylase (TH) mRNA
expression in the ventral tegmental area. (b) A signiﬁcant
negative correlation was found between the binding densities
of D2 receptor and dopamine transporter in the nucleus
accumbens core.

DAT binding
Examples of DAT binding are presented in Fig. 4 d, e.
NAcC. There was a signiﬁcant eﬀect of drug treatment
(F3,32=12.057, p=0.000), but no signiﬁcant eﬀect of
treatment period (F1,39=1.578, p=0.218) on DAT
binding in NAcC. There was also no signiﬁcant interaction between the two factors (F3,32=0.789, p=0.509).
Compared to the control group, DAT binding density
was signiﬁcantly decreased in the 1- and 12-wk
aripiprazole and haloperidol groups (Fig. 5 d). However, in the olanzapine group, a signiﬁcant diﬀerence
was observed only after 1-wk treatment (olanzapine 29.7¡3.7 vs. control 41.2¡7.1, p=0.018), although

VTA. There were signiﬁcant eﬀects of drug treatment
on DAT binding in VTA (F3,32=4.214, p=0.013) and no
eﬀect of treatment period (F1,39=0.044, p=0.836).
However, a signiﬁcant interaction between drug treatment and treatment period was observed (F3,32=5.731,
p=0.003). After 1-wk treatment, the aripiprazole
group (10.1¡0.6 fmol/mg TE) had signiﬁcantly lower
DAT binding density compared to the control group
(13.7¡0.7 fmol/mg TE, p=0.03 ; Fig. 5 f), but was
not signiﬁcantly diﬀerent from the other groups.
After 12-wk drug treatment only the haloperidol
(9.7¡0.7 fmol/mg TE) group had signiﬁcantly lower
DAT binding density than controls (12.5¡0.5, p=
0.048) (Fig. 5 f). However, there were no eﬀects of drug
treatment and treatment period on DAT binding in
NAcS and SN.
Discussion
This study has showed that aripiprazole has selective
eﬀects on mesolimbic vs. nigrostriatal dopaminergic
pathways. Aripiprazole signiﬁcantly increased D2 receptor mRNA expression in VTA and CPu compared
to controls after 1- and 12-wk treatment, but not in
SN and NAc. Aripiprazole also signiﬁcantly downregulated TH mRNA expression in the VTA, but not in
SN, compared to controls. It is interesting that D2 receptor mRNA expression is negatively correlated with
TH mRNA expression in the VTA. Aripiprazole also
decreased DAT binding sites in NAc (both 1- and 12wk treatment) and VTA (1-wk treatment). In contrast,
haloperidol had a signiﬁcant inﬂuence on mesolimbic
and nigrostriatal dopaminergic pathways. Haloperidol treatment increased D2 receptor binding in CPu
and NAc after 1- and 12-wk treatment, but decreased
DAT binding in CPu and NAc (1- and 12-wk treatment), as well as VTA (12-wk treatment). Olanzapine
had less widespread eﬀects compared to the other two
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Fig. 4. Autoradiographic images taken using a Beta image camera (BioSpace, Paris) showing the high binding density of (c)
D2 receptor and (d, e) dopamine transporter in the nucleus accumbens core (NAcC), nucleus accumbens shell (NAcS), caudate
putamen (CPu) and ventral tegmental area (VTA) in the rat brain. Maps (a) and (b) are adapted from a standard rat brain atlas
(Paxinos & Watson, 1997).
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Fig. 5. The binding densities of (a–c) D2 receptor and (d–f ) dopamine transporter (DAT) in rats treated with aripiprazole (Ari),
olanzapine (Olz), haloperidol (Hal) and vehicle (Con) in the nucleus accumbens core (NAcC), caudate putamen (CPu) and
ventral tegmental area (VTA). Compared to control : * p<0.05, ** p<0.01. %, 1-wk treatment ; &, 12-wk treatment.

treatments, namely an increase in DAT binding in
NAcC (1-wk treatment only) and D2 receptor mRNA
expression in VTA (12-wk treatment only).
A series of short-term (4–6 wk) and longer term (26
or 52 wk) clinical trails have revealed that aripiprazole
not only has signiﬁcant short- but also long-term eﬃcacy in the treatment of positive and negative symptoms of schizophrenia (Cassano et al. 2007 ; DeLeon

et al. 2004 ; Kane et al. 2007 ; Kasper et al. 2003 ; Travis
et al. 2005). Compared with placebo, aripiprazole improved symptoms of schizophrenia as early as 1 wk
after treatment (Travis et al. 2005), and this eﬃcacy
lasted up to 52 wk (Kasper et al. 2003). It has been
suggested that the partial agonism of dopamine D2
receptors is one of the mechanisms underlying the
therapeutic eﬀects of aripiprazole (Wood & Reavill,
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2007). However, it is worth noting that another D2 receptor partial agonist (preclamol) also decreases positive and negative symptoms of schizophrenia, but its
eﬀects only last for 1 wk (Lahti et al. 1998). Therefore,
the partial agonism of dopamine D2 receptors cannot
completely explain the long-term eﬃcacy of aripiprazole. TH mRNA expression in VTA was decreased in the aripiprazole group in the present study.
Since TH is the rate-limiting enzyme for the synthesis
of dopamine, this indicates a reduction of dopamine
synthesis in this brain region. The selective eﬀects of
aripiprazole on reducing dopamine production found
in the present study may provide a mechanism to explain its long-term eﬃcacy.
A reduction in dopamine synthesis may be mediated by D2 autoreceptors (Wolf & Roth, 1990). Previously, in-vivo studies have found that aripiprazole
has potent agonist activities at dopamine autoreceptors (Kikuchi, 1995). Aripiprazole may act on
these D2 autoreceptors in the VTA to reduce chronic
dopamine synthesis, and continual treatment of aripiprazole would reduce dopamine release. Although a
single low-dose (0.3 mg/kg) administration of aripiprazole increases dopamine release (Zocchi et al.
2005), a higher dose (2–40 mg/kg) decreases or has no
eﬀect on extracellular levels of dopamine in the rat
cortex and striatum (Jordan et al. 2004 ; Zocchi et al.
2005). It follows that in our experiment, aripiprazole
treatment (2.5 mg/kg.d) for 1 or 12 wk should decrease dopamine release. As a compensatory mechanism, D2 autoreceptor synthesis in the VTA may be
increased in response to the decrease of dopamine
synthesis and release caused by aripiprazole treatment. Consistent with this, an increase in D2 receptor
mRNA expression was observed in VTA of the aripiprazole group. In fact, a negative correlation between D2 receptor mRNA and TH mRNA expressions
was found in this brain region. This suggests that aripiprazole may achieve its pharmacological eﬀects by
reducing dopamine production in VTA. Moreover,
since the eﬀects of aripiprazole on D2 receptor mRNA
and TH mRNA expression have been observed after
1- and 12-wk treatment, our theory may well explain
its fast eﬀects (1 wk) on improving symptoms and its
long-term eﬃcacy maintenance. It is interesting that
aripiprazole had no eﬀect on D2 receptor mRNA expression and D2 receptor binding in NAc. It is possible
that aripiprazole reaches its long-term eﬃcacy by reducing dopamine levels in the VTA–NAc pathway,
but not directly through blocking post-synaptic D2 receptors in the NAc.
In this study, like haloperidol, olanzapine increased
D2 receptor mRNA expression in VTA after 12-wk

treatment, but it did not change in TH mRNA expression. Since olanzapine has relatively low aﬃnity
for D2 receptors but high aﬃnity for 5-HT2A, 5-HT2C
and M1 receptors (DeLeon et al. 2004), it has been
suggested to achieve its pharmacological eﬀects
through its actions on these neurotransmission systems (Tyson et al. 2004). In fact, we have previously
found that chronic olanzapine treatment downregulated 5-HT2A receptor mRNA expression in NAc
(Huang et al. 2006) and up-regulated muscarinic M1
receptor mRNA expression in the hippocampus (Han
et al. 2008b).
It is an exciting ﬁnding that aripiprazole has diﬀerential eﬀects on the VTA–NAc pathway compared to
the SN–CPu pathway. Aripiprazole did not aﬀect the
expression of D2 receptor mRNA or TH mRNA in SN.
This result suggests that there are no changes in dopamine synthesis in SN, which may be due to the fact
that D2 autoreceptors in VTA are about 10-fold more
sensitive to dopamine and D2 receptor agonists than
those in SN (Roth, 1979). Although 1-wk aripiprazole
treatment slightly increased D2 receptor mRNA expression in CPu compared with controls, this diﬀerence disappeared after 12-wk treatment. It is also
interesting that 1- and 12-wk aripiprazole treatment
did not aﬀect D2 receptor binding in CPu in this study.
Therefore, the absence of changes to dopaminergic
transmission in the SN–CPu pathway following
chronic treatment of aripiprazole may partially explain why aripiprazole does not cause serious EPS
after long-term treatment in the clinic. However, a recent human PET study using [18F]Fallypride has
shown that aripiprazole occupies a very high percentage of the D2/D3 receptor in all brain regions investigated (including the putamen, caudate nucleus,
thalamus, amygdala, and interior temporal cortex)
(Grunder et al. 2008). Therefore, the more robust actions in mesolimbic dopamine neurons may be possibly due to the fact that the same amount of receptor
binding of aripiprazole (a partial agonist) may cause
diﬀerent functional consequences in the nigrostriatal
system.
It is important to note that a series of studies have
shown aripiprazole is a functionally selective D2 receptor ligand (Lawler et al. 1999 ; Mailman, 2007 ;
Shapiro et al. 2003 ; Urban et al. 2007). The selective
eﬀects of aripiprazole on the mesolimbic and nigrostriatal systems might be due to its properties of functional selectivity. For example, as discussed in the
Introduction, aripiprazole can act as a potent partial
agonist at D2 receptor-mediated signalling responses,
such as the potentiation of arachidonic acid release, and as a weak partial agonist at MAPK
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phosphorylation, but lacks agonist activity on receptor
internalization (Urban et al. 2007). It is possible that
aripiprazole may act as a potent agonist at dopamine
D2 autoreceptors in VTA to reduce dopamine synthesis, but as a weak agonist (or even short of agonist
activity) in SN, therefore it modulates dopaminergic
transmission mainly in the VTA–NAc pathway but
not the SN–CPu pathway.
In contrast, haloperidol aﬀected the mesolimbic and
nigrostriatal pathways by blocking D2 receptors.
Haloperidol signiﬁcantly increased D2 receptor binding density in NAc and CPu after 1- and 12-wk treatment, which is in agreement with previous reports
(Gross et al. 1991 ; Prosser et al. 1988 ; Sawa & Snyder,
2002 ; Stephen & Stahl, 2003). Some studies have also
found that haloperidol (at a dose of 1.5–4 mg/kg) increases D2 receptor mRNA expression in the striatum
(Damask et al. 1996 ; Rogue et al. 1991) ; however, the
present study did not observe any changes in D2 receptor mRNA expression in CPu. Although haloperidol increased D2 receptor mRNA expression in VTA
after 12-wk treatment, it did not cause any change in
TH mRNA expression. These results conﬁrm previous
ﬁndings that haloperidol improves schizophrenia
symptoms by blocking D2 receptors in NAc, while
causing EPS side-eﬀects by blocking D2 receptors in
CPu after chronic treatment (Kapur et al. 2000 ; Vohora,
2007). In this study, olanzapine did not aﬀect D2 receptor binding or expression of D2 mRNA and TH
mRNA in the CPu, which is consistent with a PET
study showing that olanzapine had lower D2 receptor
blockade compared to haloperidol in the striatum
(Xiberas et al. 2001). One study observed that olanzapine increased D2 receptor density in the striatum
of rats ; however, much higher doses of olanzapine
(5.0 mg/kg.d compared to 1.5 mg/kg.d in this study)
were used (Tarazi et al. 2001). These results supported
the observation that olanzapine does not cause EPS at
common clinical dosages (Vohora, 2007).
Consistent with the changes of D2 receptor and
TH mRNA expression, selective eﬀects of aripiprazole
treatment on DAT binding densities were also observed in mesolimbic and nigrostriatal pathways.
Since DAT mediates the re-uptake of free dopamine
from the synaptic cleft (Iversen, 1971), decreased DAT
density in NAc could be explained by decreased D2
synthesis in this nucleus as discussed above. In contrast, haloperidol treatment reduced DAT binding
densities in NAc and CPu. Although aripirazole and
haloperidol reduced DAT binding density, they might
act through diﬀerent mechanisms. Haloperidol has
previously been reported to reduce the reuptake
transport of dopamine in the striatum (McElvan &
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Schenk, 1992 ; Meiergerd et al. 1993). In addition, a
negative correlation between D2 receptor binding
density and DAT binding density was found in NAcC
in this study (Fig. 3 b). These results further suggest
that haloperidol may control schizophrenia symptoms
by D2 receptor blockade in NAc, and produce EPS by
D2 receptor blockade and prolonged free dopamine
reuptake in CPu. Olanzapine decreased DAT density
in NAc only, which suggests that olanzapine might
prolong dopamine activity in NAc.
DAT binding densities in VTA were decreased only
after 1-wk aripiprazole treatment, but returned to a
normal level after 12-wk treatment. It is interesting
why only short-term treatment of aripiprazole aﬀected
DAT binding density. In contrast haloperidol had
long-term eﬀects on DAT binding in VTA. One possible explanation is the speciﬁc proﬁle of aripiprazole
as a selective D2 receptor partial agonist. It was reported that D2 receptor agonists may increase the reuptake of dopamine via stimulating D2 autoreceptors,
but this eﬀect could be reversed by D2 receptor antagonists (Meiergerd et al. 1993 ; Parsons et al. 1993).
Since aripiprazole has dual D2 partial agonist and antagonist properties, it is possible that its dual eﬀects
may reach a balance after long-term treatment. However, haloperidol only has D2 antagonist properties
and needs long-term action to reduce DAT binding
density in VTA.
In the literature, the dosages of aripiprazole, haloperidol, and olanzapine vary signiﬁcantly in the animal studies. Similar doses to that used in this study
have been used previously in the literature and have
been shown to be pharmacologically and behaviourally eﬀective. For example, aripiprazole has been
used at doses ranging from 2 to 3 mg/kg (Kalinichev
et al. 2005 ; Li et al. 2005 ; Schwabe & Koch, 2007).
Haloperidol has frequently been utilized at a dose
of 0.3 mg/kg (Pouzet et al. 2003 ; Wiley, 2008), while
olanzapine treatments ranging from 1.2 mg/kg
(Arjona et al. 2004 ; Huang et al. 2006) to 2.0 mg/kg
(Cooper et al. 2005) have been used in rats. These
selected doses all share a D2 occupancy of y70–80 % in
rats (Kapur et al. 2003 ; Natesan et al. 2006). Furthermore, antipsychotics were administrated orally three
times a day in this study. We have shown previously
that the doses of the drugs and treatment (at three
times a day) used in this study aﬀected central receptor systems relative to their pharmacological proﬁles
(Han et al. 2008a, b ; Huang et al. 2006), indicating
the eﬀectiveness of these treatments. Since rats were
sacriﬁced 48 h after the last drug treatment, we could
not completely rule out a possible drug withdrawal
response observed 2 d after the last aripiprazole
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treatment ; however, it is unlikely. It has been shown
that aripiprazole has a long elimination half-life
(60–70 h) and exerts its eﬀects on D2/D3 receptors for
almost 1 wk after the last dose in humans (Grunder
et al. 2008). Unfortunately, there is no data available
on its half-life in rats. It is understandable that aripiprazole may have a diﬀerent half-life in rats from
that in humans ; however, even assuming a 4- to 6-fold
faster half-life of aripiprazole in rats, it may still have
eﬀects 1.5 d after the last treatment in rats. Further
studies are necessary to measure the half-life of aripiprazole in rats (particularly in the brain) and to
investigate changes of TH and D2 receptor mRNA expression a short period (e.g. a few hours) after the last
aripiprazole treatment.
In conclusion, the present results suggest that aripiprazole, unlike other antipsychotics, has selective
eﬀects on dopaminergic pathways, in which both
short- and long-term treatment predominantly modulates the dopaminergic neurotransmission in the mesolimbic but not nigrostriatal pathways. Selectively
reducing dopamine synthesis in VTA (but not SN)
is the possible therapeutic mechanism for long-term
eﬃcacy of aripiprazole in controlling schizophrenia
symptoms with less extrapyramidal side-eﬀects.
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